Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.83 |
| ▸ | ACACA | Q13085 | 15/20 | 0.83 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622325 | 1.00 | ACACB (0.83) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| SCHEMBL6183505 | 0.99 | ACACB (0.84) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| SCHEMBL6185174 | 0.95 | ACACB (0.78) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| SCHEMBL6181556 | 0.92 | ACACB (0.80) | ACACBACACAKDM2B | |
| SCHEMBL6180950 | 0.91 | ACACB (0.78) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| SCHEMBL3459079 | 0.91 | ACACB (1.00) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL6491415 | 0.91 | ACACB (0.78) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| SCHEMBL976549 | 0.91 | ACACB (1.00) | ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL6182816 | 0.90 | ACACB (0.78) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| SCHEMBL6184986 | 0.90 | ACACB (0.77) | ACACBACACAKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003767-A1 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism | NEUERA PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003767-A1 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885MBTD1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.